BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 30928162)

  • 1. Could Differences in Treatment Between Trial Arms Explain the Reduction in Prostate Cancer Mortality in the European Randomized Study of Screening for Prostate Cancer?
    Carlsson SV; Månsson M; Moss S; Kwiatkowski M; Recker F; Tammela TLJ; Bangma C; Roobol MJ; Auvinen A; Hugosson J
    Eur Urol; 2019 Jun; 75(6):1015-1022. PubMed ID: 30928162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate cancer mortality in the Finnish randomized screening trial.
    Kilpeläinen TP; Tammela TL; Malila N; Hakama M; Santti H; Määttänen L; Stenman UH; Kujala P; Auvinen A
    J Natl Cancer Inst; 2013 May; 105(10):719-25. PubMed ID: 23479454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate-specific antigen screening trials and prostate cancer deaths: the androgen deprivation connection.
    Haines IE; Gabor Miklos GL
    J Natl Cancer Inst; 2013 Oct; 105(20):1534-9. PubMed ID: 24092918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of study arm on prostate cancer treatment in the large screening trial ERSPC.
    Wolters T; Roobol MJ; Steyerberg EW; van den Bergh RC; Bangma CH; Hugosson J; Ciatto S; Kwiatkowski M; Villers A; Luján M; Nelen V; Tammela TL; Schröder FH
    Int J Cancer; 2010 May; 126(10):2387-93. PubMed ID: 19739124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Finnish prostate cancer screening trial: analyses on the screening failures.
    Kilpeläinen TP; Tammela TL; Malila N; Hakama M; Santti H; Määttänen L; Stenman UH; Kujala P; Auvinen A
    Int J Cancer; 2015 May; 136(10):2437-43. PubMed ID: 25359457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impacts of a population-based prostate cancer screening programme on excess total mortality rates in men with prostate cancer: a randomized controlled trial.
    van Leeuwen PJ; Kranse R; Hakulinen T; Hugosson J; Tammela TL; Ciatto S; Roobol MJ; Zappa M; de Koning HJ; Bangma CH; Moss SM; Auvinen A; Schröder FH
    J Med Screen; 2013 Mar; 20(1):33-38. PubMed ID: 28075228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update of the results of the Spanish branch of the European Randomized Study on Screening for Prostate Cancer (ERSPC).
    Luján M; Páez Á; Angulo JC; Andrés G; Gimbernat H; Redondo C; Torres GM; Berenguer A
    Actas Urol Esp; 2015 Sep; 39(7):405-13. PubMed ID: 25777669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term radical prostatectomy outcomes among participants from the European Randomized Study of Screening for Prostate Cancer (ERSPC) Rotterdam.
    Loeb S; Zhu X; Schroder FH; Roobol MJ
    BJU Int; 2012 Dec; 110(11):1678-83. PubMed ID: 22998182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer.
    Hugosson J; Roobol MJ; Månsson M; Tammela TLJ; Zappa M; Nelen V; Kwiatkowski M; Lujan M; Carlsson SV; Talala KM; Lilja H; Denis LJ; Recker F; Paez A; Puliti D; Villers A; Rebillard X; Kilpeläinen TP; Stenman UH; Godtman RA; Stinesen Kollberg K; Moss SM; Kujala P; Taari K; Huber A; van der Kwast T; Heijnsdijk EA; Bangma C; De Koning HJ; Schröder FH; Auvinen A;
    Eur Urol; 2019 Jul; 76(1):43-51. PubMed ID: 30824296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Prostatic-specific Antigen Threshold and Screening Interval in Prostate Cancer Screening Outcomes: Comparing the Swedish and Finnish European Randomised Study of Screening for Prostate Cancer Centres.
    Saarimäki L; Hugosson J; Tammela TL; Carlsson S; Talala K; Auvinen A
    Eur Urol Focus; 2019 Mar; 5(2):186-191. PubMed ID: 28803925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences in Treatment and Outcome After Treatment with Curative Intent in the Screening and Control Arms of the ERSPC Rotterdam.
    Bokhorst LP; Kranse R; Venderbos LD; Salman JW; van Leenders GJ; Schröder FH; Bangma CH; Roobol MJ;
    Eur Urol; 2015 Aug; 68(2):179-82. PubMed ID: 25457496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Number of Screening Rounds and Postscreening Prostate Cancer Incidence: Results from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer Study.
    Pakarainen T; Raitanen J; Talala K; Taari K; Kujala P; Tammela TL; Auvinen A
    Eur Urol; 2016 Sep; 70(3):499-505. PubMed ID: 27210461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Change of tumour characteristics and treatment over time in both arms of the European Randomized study of Screening for Prostate Cancer.
    Boevee SJ; Venderbos LD; Tammela TL; Nelen V; Ciatto S; Kwiatkowski M; Páez A; Malavaud B; Hugosson J; Roobol MJ
    Eur J Cancer; 2010 Nov; 46(17):3082-9. PubMed ID: 21047590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results of the spanish section of the European Randomized Study of Screening for Prostate Cancer (ERSPC). Update after 21 years of follow-up.
    Luján Galán M; Páez Borda Á; Llanes González L; Romero Cajigal I; Berenguer Sánchez A
    Actas Urol Esp (Engl Ed); 2020; 44(6):430-436. PubMed ID: 32147352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate-Specific Antigen-Based Screening for Prostate Cancer: Evidence Report and Systematic Review for the US Preventive Services Task Force.
    Fenton JJ; Weyrich MS; Durbin S; Liu Y; Bang H; Melnikow J
    JAMA; 2018 May; 319(18):1914-1931. PubMed ID: 29801018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy of prostate-specific antigen screening: Impact of key components in the ERSPC and PLCO trials.
    de Koning HJ; Gulati R; Moss SM; Hugosson J; Pinsky PF; Berg CD; Auvinen A; Andriole GL; Roobol MJ; Crawford ED; Nelen V; Kwiatkowski M; Zappa M; Luján M; Villers A; de Carvalho TM; Feuer EJ; Tsodikov A; Mariotto AB; Heijnsdijk EAM; Etzioni R
    Cancer; 2018 Mar; 124(6):1197-1206. PubMed ID: 29211316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional Outcomes After Localized Prostate Cancer Treatment.
    Al Hussein Al Awamlh B; Wallis CJD; Penson DF; Huang LC; Zhao Z; Conwill R; Talwar R; Morgans AK; Goodman M; Hamilton AS; Wu XC; Paddock LE; Stroup A; O'Neil BB; Koyama T; Hoffman KE; Barocas DA
    JAMA; 2024 Jan; 331(4):302-317. PubMed ID: 38261043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reducing prostate cancer deaths: unsupported speculation about the androgen deprivation hypothesis.
    Carter HB
    Eur Urol; 2014 Dec; 66(6):973-4. PubMed ID: 25018035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Göteborg randomized population-based prostate cancer screening trial.
    Arnsrud Godtman R; Holmberg E; Lilja H; Stranne J; Hugosson J
    Eur Urol; 2015 Sep; 68(3):354-60. PubMed ID: 25556937
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.